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Osteogenic Factor Runx2 Marks a 
Subset of Leptin Receptor-Positive 
Cells that Sit Atop the Bone Marrow 
Stromal Cell Hierarchy
Mengyu Yang1, Atsushi Arai2, Nobuyuki Udagawa3, Toru Hiraga4, Zhao Lijuan1, Susumu Ito5, 
Toshihisa Komori6, Takeshi Moriishi6, Koichi Matsuo7, Kouji Shimoda8, Ali H. Zahalka9,10, 
Yasuhiro Kobayashi1, Naoyuki Takahashi1 & Toshihide Mizoguchi1
Bone marrow mesenchymal stem and progenitor cells (BM-MSPCs) maintain homeostasis of bone 
tissue by providing osteoblasts. Although several markers have been identified for labeling of MSPCs, 
these labeled cells still contain non-BM-MSPC populations. Studies have suggested that MSPCs are 
observed as leptin receptor (LepR)-positive cells, whereas osteoblasts can be classified as positive for 
Runx2, a master regulator for osteoblastogenesis. Here, we demonstrate, using Runx2-GFP reporter 
mice, that the LepR-labeled population contains Runx2-GFPlow sub-population, which possesses higher 
fibroblastic colony-forming units (CFUs) and mesensphere capacity, criteria for assessing stem cell 
activity, than the Runx2-GFP− population. In response to parathyroid hormone (PTH), a bone anabolic 
hormone, LepR+Runx2-GFPlow cells increase Runx2 expression and form multilayered structures near 
the bone surface. Subsequently, the multilayered cells express Osterix and Type I collagen α, resulting 
in generation of mature osteoblasts. Therefore, our results indicate that Runx2 is weakly expressed in 
the LepR+ population without osteoblastic commitment, and the LepR+Runx2-GFPlow stromal cells sit 
atop the BM stromal hierarchy.
Bone marrow (BM) cells belonging to mesenchymal lineages are derived from mesenchymal stem and progenitor 
cells (MSPCs). BM-MSPCs are traditionally characterized as cells possessing colony forming potential in adherent 
culture conditions [known as colony-forming unit-fibroblasts, CFU-F] and have the ability to form clonal spheres 
in nonadherent culture conditions [designated as mesenspheres]1–3. The clonally expanded CFU-F colonies and 
mesenspheres have differentiation potential to osteoblasts, adipocytes and chondrocytes both in vitro and in 
vivo. BM-MSPCs can be marked by the expression of leptin receptor (LepR)-Cre, and are distributed nearby 
blood vessels throughout the whole BM cavity4–6. In vivo fate mapping approaches demonstrated that LepR+ cells 
differentiate to osteoblasts and adipocytes under normal conditions. The contribution of LepR+ cells to chon-
drocytes is observed during the healing process of bone tissue5, 6. There is evidence that LepR-Cre-labeled cells 
largely overlap with other markers for the BM-MSPC populations including CD31−CD45−Ter119−Nestin-GFPlow 
cells5, 7, CXCL12 abundant reticular (CAR) cells8, 9, PDGFRβ+ cells5, 6 and Prx-1-Cre labeled cells10. Although 
these markers make it possible to enrich the BM-MSPCs from whole BM cells, not all the labeled cells have the 
1Institute for Oral Science, Matsumoto Dental University, Nagano, 399-0781, Japan. 2Department of Orthodontics, 
Matsumoto Dental University, Nagano, 399-0781, Japan. 3Department of Oral Biochemistry, Matsumoto Dental 
University, Nagano, 399-0781, Japan. 4Department of Histology and Cell Biology, Matsumoto Dental University, 
Nagano, 399-0781, Japan. 5Division of Instrumental Analysis, Research Center for Human and Environmental 
Sciences, Shinshu University, Nagano, 390-8621, Japan. 6Department of Cell Biology, Unit of Basic Sciences, 
Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, 852-8588, Japan. 7Laboratory of Cell 
and Tissue Biology, Keio University School of Medicine, Tokyo, 160-8582, Japan. 8Laboratory Animal Center, Keio 
University School of Medicine, Tokyo, 160-8582, Japan. 9Ruth L. and David S. Gottesman Institute for Stem Cell and 
Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY, 10461, USA. 10Department of Cell 
Biology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA. Mengyu Yang and Atsushi Arai contributed 
equally to this work. Correspondence and requests for materials should be addressed to T.M. (email: toshim@
po.mdu.ac.jp)
Received: 30 January 2017
Accepted: 6 June 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 4928  | DOI:10.1038/s41598-017-05401-1
potential to form CFU-F colonies or clonal mesenspheres6, 7, 11. These results suggest that the fractions are impure 
and still contain non-BM-MSPC populations.
Runt-related transcription factor 2 (Runx2) is a master regulator for osteoblast differentiation12–14. 
Osteoblastogenesis is fully suppressed by the global knockout of Runx213, 14. Exon 8 of Runx2 gene conditional 
deletion in mature osteoblasts, which express Cre recombinase under the control of a 2.3-kb fragment of the type 
I collagen α[(Col1(2.3)] promoter, exhibit low bone mass phenotype15. In contrast, conditional knockout mice 
lacking exon 4 of Runx2 gene in mature osteoblasts have no effect on osteoblastic activity16. These studies indicate 
that the necessity of Runx2 in osteoblastic activity is still controversial. On the other hand, in vivo lineage trac-
ing studies have demonstrated that Runx2 is essential for osteoblast lineage commitment17. Interestingly, Runx2 
overexpression approaches revealed that the late stage of osteoblastogenesis is negatively regulated by Runx2, 
whose levels were found to decrease with osteoblast maturation18, 19. Overall, these findings suggest that Runx2 is 
required for osteoblast commitment from immature mesenchymal stromal cells. These results raise the intriguing 
possibility that Runx2 may be expressed in a portion of LepR+ stromal cells, which have osteogenic-committed 
sub-populations.
Osteoblastogenesis is completely diminished in knockout mice lacking Osterix (Osx), a transcription factor 
that acts downstream of Runx220. Furthermore, bone formation is inhibited by conditionally deleting Osx in 
mature osteoblasts21. These results suggest that Osx is necessary not only for osteoblast differentiation, but also 
for their functions. On the other hand, during endochondral bone ossification, BM-MSPCs are generated from 
part of the developing chondrogenic cell populations17. The expression levels of Osx are increased throughout the 
development of chondrogenic cell populations that subsequently differentiate into BM-MSPCs5, 17, 22. Although 
Osx protein expression in BM-MSPCs is completely lost in the adult stage, mRNA expression is maintained5, 23. 
However, the Osx expression pattern during osteoblastogenesis from BM-MSPCs has yet to be elucidated.
Teriparatide, a biologically active amino acid 1–34 fragment of human PTH [hPTH (1–34)], is clinically 
used in treatment of osteoporosis patients24. Several studies have demonstrated that intermittent PTH treatment 
induces remedial action against osteoporosis due to anabolic effects on bone tissue25–28. Researchers have found 
that osteoblast precursors are increased along the bone surfaces in response to PTH treatment27–30. These results 
suggest that the anabolic effects of PTH on bone tissue are exerted by the acceleration of osteoblastogenesis from 
immature BM mesenchymal precursors. However, it still remains unclear which BM stromal cells give rise to 
osteoblasts in response to PTH treatments, thereby mediating the therapeutic response in osteoporosis.
Here we demonstrate, using Runx2-GFP reporter mice, that the LepR+ cell population contains Runx2-GFPlow 
cells, and unexpectedly, that stem cell capacity is enriched in the Runx2-GFPlow sub-population. In addition, our 
studies have shown that the LepR+Runx2-GFPlow cells differentiate into mature osteoblasts via multilayered cell 
formation adjacent to bone surfaces in response to PTH-induced bone anabolic effects. These results provide 
evidence that LepR+Runx2-GFPlow cells sit atop the BM mesenchymal stromal cell hierarchy.
Results
Runx2 is heterogeneously expressed in the LepR+ BM stromal cell population. To detect Runx2 
expressing cells in bone tissue, we analyzed Runx2-GFP reporter mice, in which GFP is driven by a bacterial 
artificial chromosome (BAC) of Runx2 locus31. FITC-conjugated anti-GFP antibody was used to amplify the 
intensity of the GFP signal when imaging bone tissue sections. Consistent with a previous study31, Runx2-GFP+ 
expression in bone tissues was detected in osteoblasts, osteocytes and chondrocytes (Fig. 1A–D). Interestingly, the 
Runx2-GFP signal was observed not only in bone tissues, but also in the BM cavity (Fig. 1A, right panel). Some 
hematopoietic cells were observed as GFP-positive cells due to nonspecific binding of the anti-GFP antibody 
(compare wild-type and Runx2-GFP mice in Fig. 1E). On the other hand, VE-cadherin (VE-Cad) and CD31-
positive endothelial cells, and Perilipin-positive adipocytes did not express Runx2-GFP (Fig. 1F,G). It is interest-
ing to note that leptin receptor-positive (LepR+) BM stromal cells, which are considered to have characteristics 
of BM-MSPCs, also weakly expressed Runx2-GFP throughout the bone marrow cavity (Fig. 1H). These results 
indicate that the osteoblastic master regulator Runx2 may already be expressed in the pre- or early osteoblastic 
lineage-committed LepR+ sub-population.
To further analyze Runx2-GFP expression pattern in the BM stromal population, we performed flow cytomet-
ric analyses of BM cells in the Runx2-GFP mice. Runx2-GFP+ cells were observed in the BM stromal cell popula-
tion without enhancing the GFP signal by FITC-conjugated anti-GFP antibody (Fig. 2A). We found two distinct 
types of Runx2-GFP+ cells on the basis of their GFP expression levels and cellular morphology (designated as 
Runx2-GFPlow and -GFPhigh cells) (Fig. 2A). Most of the Runx2-GFPlow cells (82.0 ± 1.4%), but not Runx2-GFPhigh 
cells (3.3 ± 1.8%), were positive for LepR (Fig. 2A). Previous reports suggested that mature osteoblasts are neg-
ative for LepR5, 6. These results indicate that the mature osteoblasts are contained in the Runx2-GFPhigh popula-
tion. Next, we analyzed the Runx2-GFP expression pattern in LepR+ cells. Interestingly, most of the LepR+ cells 
were positive for Runx2-GFP (64.6 ± 2.0%) (designated as LepR+Runx2-GFPlow cells) (Fig. 2B, right panel). The 
frequency and absolute number of LepR+Runx2-GFPlow cells per femur were approximately 3-times higher than 
those of LepR+Runx2-GFP− cells (Fig. 2C,D). These results indicate that LepR+ cells consist of two populations: 
LepR+Runx2-GFPlow and LepR+Runx2-GFP− sub-populations.
Stem cell activity is enriched in the Runx2-GFPlow sub-population of LepR+ cells. Upregulation 
of Runx2 expression is thought to indicate osteoblastic commitment of multipotent BM stromal progenitors32. 
We next generated LepR-Cre/ROSA26-loxP-stop-loxP-tdTomato/Runx2-GFP (LepR/Tomato/Runx2-GFP) mice, 
and analyzed whether stem cell activity in LepR+ cells increases in inverse proportion to Runx2 expression levels. 
Previous reports demonstrated that the differentiation of LepR+ cells into mature osteoblasts is mainly observed 
in adult mice, and only rarely seen in young mice5, 6. In order to avoid contamination of the LepR-Cre-labeled 
population with LepR+ cell-derived osteoblasts, we analyzed young mice (5–7 weeks old) in this experiment. 
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Histological analysis demonstrated that bone-lining osteoblasts were strongly positive for Runx2-GFP, but 
negative for LepR/Tomato (Fig. 3A, asterisks). These results indicate that LepR-Cre-labeled Tomato+ (LepR/
Tomato+) cells do not contain the osteoblastic population in young mice. On the other hand, the LepR/Tomato+ 
cells in the BM cavity were positive for Runx2-GFP (Fig. 3A, arrows). Immunofluorescence staining showed that 
LepR/Tomato+ cells express Runx2 protein (Fig. 3B, arrows). Flow cytometric analysis also demonstrated that 
the majority of LepR/Tomato+ cells in BM expressed Runx2-GFP (60.9 ± 2.5%) (Fig. 3C). We then assessed the 
stem cell activity of both Runx2-GFPlow and Runx2-GFP− sub-populations in LepR/Tomato+ cells by performing 
CFU-F assays of cell sorted BM stromal fractions (Fig. 3D). Consistent with previous reports6, 7, there were no 
CFU-F capable cells in the LepR/Tomato− BM stromal population (Fig. 3D). Contrary to our expectations, the 
CFU-F capacity of the LepR/Tomato+/Runx2-GFPlow BM stromal population was high (Fig. 3D). CFU-F colo-
nies derived from the LepR/Tomato+/Runx2-GFPlow BM stromal population were positive for LepR/Tomato and 
weakly Runx2-GFP-positive (Fig. 3E,F). Furthermore, when BM stromal fractions were plated at clonal densities 
under nonadherent culture conditions, the LepR/Tomato+/Runx2-GFPlow population formed spheres (mesen-
spheres) at greater frequency than other fractions (Fig. 3G,H). The LepR/Tomato+/Runx2-GFPlow BM stromal 
cells exhibited tri-lineage differentiation potential (Fig. 3I–K). However, it is not clear whether the LepR/Tomato+/
Runx2-GFPlow BM stromal cells generate other types of BM stromal cells. Real-time PCR analyses revealed that the 
LepR/Tomato− sub-population did not express the MSPC markers PDGFRa7, 33 LepR5, 6 or CXCL1223(Fig. 3L–N). 
Interestingly, the expression levels of all three of these MSPC markers in the LepR-Cre/Tomato+Runx2-GFPlow 
sub-population were significantly higher than in the LepR-Cre/Tomato+Runx2-GFP− sub-population (Fig. 3L–N). 
These results also indicated that the LepR-Cre/Tomato+Runx2-GFPlow sub-population overlaps with CXCL12 
abundant reticular (CAR) cells23, which are generated from part of the developing chondrogenic cell popula-
tions17. The expression levels of Runx2 mRNA in the Runx2-GFPlow sub-population were significantly higher than 
those in the Runx2-GFP− sub-population from LepR-Cre/Tomato+ stromal cells (Fig. 3O). The Runx2 expression 
was hardly detected in the LepR-Cre/Tomato− stromal cell population at the mRNA level (Fig. 3O). Consistently, 
the LepR-Cre/Tomato− stromal population contained almost no Runx2-GFP+ cells (0.7 ± 0.2%) (Suppl. Fig. 1). 
Taken together, these results indicate that stromal stem cell activity in BM is high in LepR+ Runx2-GFPlow stromal 
cell populations. Therefore, our findings provide evidence that LepR+ Runx2-GFPlow cells sit atop the BM stromal 
cell hierarchy, and the osteoblastic master transcription factor Runx2 is weakly expressed in BM-MSPC popula-
tions without osteoblastic lineage commitment.
Figure 1. LepR+ cells in the bone marrow cavity express Runx2. (A–H) Z-stack confocal (A,D–F and H) and 
confocal (B,C and G) images of thick bone sections of Runx2-GFP mice (5–6 weeks old). The images were taken 
from whole bone tissue (A), endosteum (B,C and F), epiphyseal cartilage (D) and bone marrow (E,G and H). 
Bone tissues are stained with osteocalcin (Red) (B), SOST (Red) (C), Type-2 collagen (Col2) (Red) (D), CD45 
and Ter119 (Red) (E), VE-cadherin (VE-Cad) and CD31 (Red) (F), Perilipin (White) (G), and Leptin receptor 
(LepR) (Red) (H) antibodies. Nuclei are visualized with Hoechst 33342 (blue) and propidium iodide (PI) (Red). 
Arrows: Osteoblasts (B), Osteocytes (C), and LepR+ cells (H).
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LepR+Runx2-GFPlow cells differentiate into osteoblasts through multilayered cell formation 
in response to PTH anabolic effects. In vivo genetic lineage tracing analysis demonstrated that LepR+ 
cells differentiate into osteoblasts5, 6. As we found that stem cell activity is enriched in LepR+Runx2-GFPlow BM 
stromal cell populations, we next examined whether LepR+Runx2-GFPlow cells differentiate into mature osteo-
blasts in vivo by lineage tracing. Because intermittent treatment of parathyroid hormone (PTH) (1–34) increased 
bone volume by inducing bone formation (Suppl. Fig. 2)24–26, 28, we injected PTH into LepR/Tomato/Runx2-GFP 
mice. Bone-lining osteoblasts were detected as Runx2-GFP single-positive cells in the control group (Fig. 4A, 
asterisks). In contrast, LepR/Tomato and Runx2-GFP double-positive mature osteoblasts were significantly 
increased on the endosteal surface in the PTH-treated bone tissue (Fig. 4B, asterisks and Suppl. Fig. 3A). These 
results suggest that osteoblastogenesis from LepR+ cells is accelerated by PTH treatment. It is noteworthy that 
Figure 2. LepR+ cells contain Runx2-GFPlow and Runx2-GFP− sub-populations. (A) Representative FACS plots 
(gated on live CD45−Ter119−CD31− cells) showing the expression of LepR in Runx2-GFP+ stromal populations 
from 5 week-old Runx2-GFP mice. Left panel showing representative FACS plot of WT control (gated on live 
CD45−Ter119−CD31− cells). Black and red lines represent the isotype control and specific antibody against 
LepR, respectively. n = 3. (B) Representative FACS plots (gated on live cells) showing frequency of Runx2-GFP+ 
population in the CD45−Ter119−CD31−LepR+ cell population (right panel) from 5–6 week-old Runx2-GFP 
mice. Left panel showing negative control for LepR antibody (gated on live cells). Black and red lines represent 
the WT control and Runx2-GFP mice, respectively (right panel). n = 3. (C and D) Quantification of the 
frequency (C) and absolute number (D) of Runx2-GFPlow and Runx2-GFP− sub-populations in LepR+ cells 
(CD45−Ter119−CD31−). n = 3. *P < 0.05, **P < 0.01. Data are represented as mean ± SD.
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Figure 3. Stromal stem cell activity in BM is enriched in LepR+Runx2-GFPlow population. (A) Z-stack 
confocal images of thick bone sections of 6 week-old LepR-Cre/Tomato/Runx2-GFP mice. Arrows: 
LepR-Cre-derived Tomato+ (LepR/Tomato+)/Runx2-GFPlow cells. Arrowheads: LepR/Tomato+/Runx2-
GFP− cells. *: Runx2-GFPhigh bone-lining mature osteoblasts. Nuclei were visualized with Hoechst 33342 
(blue). (B) Z-stack confocal images of thick bone sections of 6 week-old LepR-Cre/Tomato mice stained 
with Runx2 (left panel, green) and control IgG (right panel). Arrows: LepR/Tomato+/Runx2+cells. Nuclei 
are visualized with To-PRO-3 (blue). (C) Representative FACS plots (gated on live cells) showing the 
percentages of Runx2-GFP-positive (designated as Runx2-GFPlow) and -negative (designated as Runx2-
GFP−)cells (middle panel) in the CD45−Ter119−CD31−LepR/Tomato+ stromal population (left panel) from 
6 week-old LepR-Cre/Tomato/Runx2-GFP mice. Right panel showing representative FACS plot of control 
(gated on live CD45−Ter119−CD31−LepR/Tomato+ cells) in 6 week-old LepR-Cre/Tomato mice. (D–O) 
CD45−Ter119−CD31− stromal cells (gated on live cells) were sorted based on expression of LepR-Cre/Tomato 
and Runx2-GFP from 6-7 week-old LepR-Cre/Tomato/Runx2-GFP mice, and percentage of CFU-F (D) and 
clonal sphere (mesensphere) formation (G) were determined. Representative image of CFU-F colony (E; 
Giemsa staining, F; Tomato and GFP fluorescence). n = 3 independent experiments. Arrows: LepR/Tomato 
and Runx2-GFP double-positive cells. Representative image of mesensphere formation (H; bright field, 
Tomato, and GFP fluorescence). n = 3 independent experiments. Differentiation phenotypes of LepR/Tomato+/
Runx2-GFPlow cells shown by Alizarin Red S: osteoblasts (I), lipid droplets and staining with FABP4 antibody: 
adipocytes (J), and Alcian Blue: chondrocytes (K). Expression levels of LepR (L), PDGFRa (M), CXCL12 (N) 
and Runx2 (O) were measured by quantitative real-time PCR. n = 3–5. *P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001. Data are represented as mean ± SD.
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while LepR+Runx2-GFPlow cells were observed in the control BM cavity (Fig. 4A and Suppl. Fig. 4A, arrows), 
LepR+Runx2-GFP+ multilayered cells (designated as ML-cells) were observed in the vicinity of bone tissue by 
PTH treatment (Fig. 4B and Suppl. Fig. 4B, arrows). Quantification of vertical- and cross-section images revealed 
that ML-cells were significantly increased by PTH treatment (Suppl. Figs 3B and 4C–E). The expression level of 
Runx2-GFP in ML-cells was higher than in LepR+Runx2-GFPlow cells (Fig. 4A,B, right panels, arrows). In con-
trast, the expression level of Runx2-GFP in ML-cells was lower than in cuboidal-shaped osteoblasts (Fig. 4B, right 
panel, arrows and asterisks). These results suggest that the LepR+Runx2-GFPlow cells differentiate into mature 
osteoblasts through ML-cell formation with increasing levels of Runx2 expression.
Figure 4. LepR+Runx2-GFPlow cells differentiate into osteoblasts through multilayered cell formation in 
response to PTH-induced anabolic effects. (A–F) Z-stack confocal images of thick bone sections of 6 week-old 
LepR-Cre/Tomato/Runx2-GFP mice (A and B), tamoxifen-administered iOsx/Tomato/Runx2-GFP mice (C 
and D), and tamoxifen-administered iOsx/Tomato/Col1(2.3)-GFP mice (E and F) with vehicle (A,C and E) 
and hPTH(1–34) (B,D and F) intermittent treatment. Arrows: LepR-Cre-derived Tomato+(LepR/Tomato+)
Runx2-GFP+ cells (A and B), iOsx/Tomato+Runx2-GFP+ cells (D) and iOsx/Tomato+Col1(2.3)-GFP+ cells (F). 
Arrowheads: iOsx/Tomato−Runx2-GFP+ cells (C and D) and iOsx/Tomato+Col1(2.3)-GFP− cells (F). *: Bone-
lining mature osteoblasts. Nuclei were visualized with To-PRO-3 (blue).
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LepR+Runx2-GFPlow cell-derived multilayered cells differentiate into mature osteoblasts with 
increasing expression of Osterix and type I collagen α. We next analyzed the expression pattern 
of Osterix (Osx), a transcription factor downstream of Runx2, in ML-cells using Osx-CreERT2(iOsx)/Tomato/
Runx2-GFP mice, administering tamoxifen for labeling of Osx+ cells34. Histological analyses demonstrated that 
mature osteoblasts express both iOsx/Tomato and Runx2-GFP, but Runx2-GFPlow cells located away from bone 
surfaces were negative for iOsx/Tomato (Fig. 4C, asterisks and arrowheads). ML-cells located far from osteoblasts 
were iOsx/Tomato negative, but those near bone-lining osteoblasts were positive for Tomato (Fig. 4D, arrow-
heads and arrows). Both the iOsx/Tomato-negative and -positive ML-cells (Runx2-GFP+ cells) were significantly 
increased by the PTH treatment (Suppl. Fig. 3C and D).
Lastly, we examined the hierarchical relationship between Osx and Type-1 collagen α (Col1), a marker 
for mature osteoblasts, in osteoblastogenesis from ML-cells using iOsx/Tomato/Col1(2.3)-GFP mice. 
Tamoxifen-induced iOsx/Tomato+ cells were observed as mature osteoblasts with Col1(2.3)-GFP expres-
sion in control bone tissue (Fig. 4E, asterisks). However, iOsx/Tomato+ cells were observed as ML-cells after 
PTH-treatment (Fig. 4F). Only the population of these cells localized in the vicinity of the bone surface overlapped 
with Col1(2.3)-GFP expression (Fig. 4F, compare arrowheads and arrows). Both the Col1(2.3)-GFP-negative and 
-positive ML-cells (iOsx/Tomato+ cells) were significantly increased by the PTH treatment (Suppl. Fig. 3E and F). 
These results thus suggest that LepR+Runx2-GFPlow cells differentiate into ML-cells adjacent to the bone surface, 
and that PTH treatment enhances Runx2 expression, which subsequently induces Osx expression, resulting in 
differentiation into Col1+ mature osteoblasts (Fig. 5).
Discussion
To clarify in vivo osteoblastogenesis from LepR+ cells, we analyzed the expression pattern of the early osteoblastic 
transcription factor, Runx2, in LepR+ cells using Runx2-GFP transgenic mice31. Here we report that BM-MSPCs 
in adult BM are confined to the weak Runx2-GFP-expressing LepR+ stromal cell population, which differentiates 
into Col1+ mature osteoblasts in response to PTH anabolic effects. In this process, the LepR+Runx2-GFPlow cells 
form multilayered structures along the bone surface, subsequently increasing expression levels of Runx2 and Osx.
Our results demonstrating that the stem cell capacity is enriched in Runx2-GFPlow populations are consistent 
with recently published data in which the most primitive stromal population in the calvaria, gated as Prx1+Scal+ 
cells, expresses Runx2 at low levels35. On the other hand, a single-cell assay demonstrated that CXCL12 abundant 
reticular (CAR) cells, which largely overlap with the LepR+ cell population, express not only Runx2 and Osx, but 
also peroxisome proliferator-activated receptor γ (PPARγ), an essential transcription factor for adipogenesis36, at 
the mRNA level23. Interestingly, osteoblastogenesis is enhanced by decreased transcriptional activity and haplo-
insufficiency of PPARγ in BM stromal progenitors37, 38. In contrast, adipogenesis is accelerated due to the stromal 
deletion of Wnt/β-catenin-signaling, an essential signaling pathway for osteoblastogenesis39. These reports sug-
gest that the undifferentiated state of LepR+Runx2-GFPlow cells is sustained due to reciprocal inhibition between 
osteogenic and adipogenic factors. Several studies have reported that the lineage differentiation of BM-MSPCs 
is skewed toward osteoblasts by intercellular expression of vascular endothelial growth factor A (VEGF-A)40. In 
contrast, the adipocyte lineage commitment from BM-MSPCs is increased by up-regulation of MicroRNA-18841, 
deletion of transcription factor Foxc19 and peripheral Leptin/Leptin receptor signaling10. Further studies will 
clarify the mechanistic details of the cell fate decision of BM-MSPCs.
Figure 5. Differentiation model of LepR+Runx2-GFPlow cells into osteoblasts. LepR+Runx2-GFPlow cells form 
multilayered structures along the bone surface in response to intermittent PTH treatment. In this process, the 
LepR+Ranx2-GFPlow cells increase the expression levels of Runx2, Osx and Col1 sequentially, and eventually 
differentiate into mature osteoblasts.
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Our data demonstrate that CFU-F and mesensphere forming capacities are rarely observed in the Runx2-GFP− 
stromal sub-population of LepR+ cells. These results indicate that the LepR+Runx2-GFP− stromal sub-population 
contains some kind of committed cells other than stem cells. Previous studies provide in vivo evidence demon-
strating that LepR+ cells differentiate into not only osteoblasts but also adipocytes with aging and during tissue 
regeneration processes after injury5, 6. In the process of adipogenesis, the expression levels of Runx2 decrease, as 
opposed to the increase of PPARγ40. Furthermore, our immunofluorescence data demonstrated that adipocytes 
are negative for Runx2 (Fig. 1G). These data suggest that the LepR+Runx2-GFP− stromal sub-population may be 
adipocyte-committed precursors. Further analysis of this fraction will provide information about the process of 
adipocytogenesis from BM-MSPCs in vivo.
In this study, we demonstrated that the PTH treatment accelerated osteoblastogenesis from 
LepR+Runx2-GFPlow cells. It has been shown that mature osteoblasts are continuously replaced by immature 
precursors in adult bone tissues42. Because the LepR+ cells differentiate into osteoblasts in adult bone tissues5, 6, 
the LepR+Runx2-GFPlow cells contribute to bone remodeling and maintain bone homeostasis in the adult phase. 
On the other hand, it has been reported that PTH anabolic effects are exerted by activation of quiescent bone 
lining osteoblasts43, suggesting that the PTH has multiple targets for bone anabolism. Our results also demon-
strate that ML-cells appear along the bone surface by PTH treatment. Consistent with our results, it is reported 
that clustered Osx-positive cells are observed as pre-osteoblasts in the vicinity of trabecular bone surfaces from 
PTH-treated rats27. Others, by employing proliferating cell labeling experiments, have also reported that the 
PTH-induced thick layered cells proliferate with expression of osteoblastic markers such as alkaline phosphatase 
(ALP), Runx2, osteocalcin and osteonectin29, 30. These results indicate that the PTH-induced osteoblastic differ-
entiation is associated with cell cycle progression. Previous studies reported that the LepR+ cells are quiescent in 
adult BM5, 6. However, the LepR+ cells markedly proliferate in response to self-depletion, and lineage differentia-
tion into both osteoblasts and adipocytes is accelerated concomitantly in this situation6. In contrast, depletion of 
the transcription factors Snail and Slug in the skeletal stem cells decreases not only proliferative activity but also 
lineage commitment potential, coincidently44. These results suggest that cell cycle quiescence may be critical for 
maintaining the undifferentiated state of BM-MSPCs. Further analysis of the mechanistic relationship between 
cell cycle regulation and lineage commitment of LepR+Runx2-GFPlow cells will provide a potential therapeutic 
target for osteoporotic patients.
Experimental Procedures
Experimental Animals. C57BL/6, B6.129-Leprtm2(cre)Rck/J (LepR-Cre), B6.Cg-Gt(ROSA)26Sortm14 
(CAG-tdTomato)Hze/J mice were purchased from Jackson Laboratory. Osx-CreERT2 mice34 were provided from 
H.M. Kronenberg. Col1(2.3)-Gfp mice45 and Runx2-Gfp mice31 were generated in one of the author’s laboratories, 
and backcrossed with C57BL/6 for 5 generations. 5–7 week-old mice were used for all experiments. All mice were 
maintained in pathogen-free conditions in animal facilities certified by the Animal Care and Use Committees of 
Matsumoto Dental University, and animal protocols were approved by that committee. All animal studies were 
performed in accordance with the Guidelines of the Matsumoto Dental University Animal Care Committee.
Antibodies and reagents. The primary antibodies used were Alexa Fluor 647-anti-VE-Cadherin and 
Alexa Fluor 647-anti-CD31/PECAM-1 (MEC13.3) (all from Biolegend); APC or PE-anti-CD45 (30-F11), APC 
or PE-anti-Ter119 (Ter119) (all from eBioscience); anti-LepR, anti-SOST/Sclerostin and anti-fatty acid binding 
protein 4 (FABP4) (all from R&D systems); anti-Osteocalcin (R21C-01A) and anti-DMP-1 (all from TAKARA); 
anti-Perilipin (Novus Biologicals); anti-chick typeII collagen (A2-10) (Chondrex); anti-Runx2 (D1L7F) (Cell 
Signaling). The secondary antibodies used were Alexa Fluor 647 donkey anti-goat IgG and Alexa Fluor 594 
donkey anti-rat IgG (all from Molecular probes); Cy3 donkey anti-mouse IgG (Merck Millipore); FITC don-
key anti-rabbit IgG (Bethyl Laboratories). Alexa Fluor 488-anti-GFP (Molecular Probes) was used for enhance-
ment of the Runx2-GFP signal. Nuclei were stained with Hoechst 33342 (Sigma-Aldrich) or TO-PRO-3 Iodide 
(642/661) (Molecular Probes).
PTH treatment and induction of Cre-mediated recombination. Human PTH (1-34) was kindly pro-
vided from Asahi Kasei Pharma Co. Ltd. Four-six-week-old mice were intraperitoneally injected with PTH (80 
μg/kg/12 hours) for 10 days. Forty-eight hours after the final PTH injection, mice were sacrificed and used for 
analyses. For induction of Cre-mediated recombination in Osx-CreERT2 mice, CRF-1 chow diet (Oriental Yeast) 
containing tamoxifen (Sigma-Aldrich) at 400 mg/kg was given from 5 days before the first PTH injection until 
the end of the experiment.
Microscopy imaging. Mice were perfused with 4% paraformaldehyde (PFA) for fixation, and bone tissue 
were further fixed with 4% PFA for 24 hours at 4 °C, and incubated in 10%, 20% and 30% sucrose each for 2 hours 
at 4 °C for cryoprotection, then embedded in 5% carboxymethyl cellulose (SECTION-LAB). Sections, 10–20-μm 
thick, were prepared using Kawamoto’s film method46. Z-stack confocal projection images were obtained from 
2-μm interval images from 10–20-μm thick sections. Fluorescence and phase-contrast images were acquired 
using a laser-scanning confocal microscope (LSM510, Carl Zeiss) equipped with Plan-Apochromat (10×/0.45 
and 20×/0.8), ZEN and Axiovision software (Carl Zeiss). Bright-field images were acquired using a Light micro-
scope Zeiss Axiovert 200 (Carl Zeiss) equipped with Plan-NEOFLUAR (2.5×/0.075), LD A-plan (40×/0.50 Ph2) 
and Axiovision software (Carl Zeiss) and Stemi 2000-C (Carl Zeiss).
Preparation of BM cell suspension. BM was gently flushed in L-15 FACS buffer47. BM was digested with 
0.1% collagenase IV (Gibco), 0.2% Dispase (Gibco) and 20 U/ml DNase (Worthington Biochemical) in HBSS 
(Gibco) for 30 min at 37 °C.
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CFU-F assay. Mouse sorted cells were seeded at 2–3 × 103 cells per well in a 12-well adherent tissue culture 
plate using a MesenCult proliferation Kit with MesenPure (StemCell Technologies) containing 100 U/ml and 100 
μg/ml penicillin-streptomycin. Half of the media was replaced after 7 days and at day 10, cells were stained with 
Giemsa staining solution (EMD Chemicals) and adherent colonies were counted.
Spheroid formation assay. Mouse sorted cells at 1 × 103 were transferred to non-adherent 24 well plates 
(Corning) with spheroid-forming media5, 7, 47 [1:2 ratio of DMEM F12 (Gibco) and Human Endothelial Medium 
(Gibco) supplemented with 3.75% Chicken Extract (US Biological), 0.1 mM β-ME (Invitrogen), 1% Non-essential 
amino acids (Gibco), 1% Pen-strep (Gibco), 1% N2 (Gibco), 2% B27 (Gibco), 20 ng/mL human bFGF (R&D 
Systems), 20 ng/mL mouse PDGF (Peprotech), 20 ng/mL mouse oncostatin M (R&D Systems), 20 ng/mL mouse 
IGF-1 (Peprotech), 20 ng/mL mouse EGF (Peprotech)]. After 7 days, the spheroid efficiency was determined.
Cell sorting and flow cytometry. Cell sorting experiments were performed using an Aria III Cell Sorter 
(BD Biosciences). Flow cytometric analyses were carried out using a Cytomics FC 500 flow cytometer equipped 
with CXP software (all Beckman Coulter Life Sciences). Dead cells and debris were excluded by FSC, SSC, DAPI 
(Dojindo) and Fixable Viability Dye eFluor 780 (eBioscience) staining profiles. Data were analysed with FlowJo 
(Tree Star) software.
In vitro cell differentiation. Sorted LepR-Cre/Tomato+Runx2-GFPlow stromal cells were expanded using 
a MesenCult proliferation Kit with MesenPure (StemCell Technologies) containing 100 U/ml and 100 μg/ml 
penicillin-streptomycin. Osteogenic, adipogenic and chondrogenic differentiation were induced using a Mouse 
Mesenchymal Stem Cell Function Identification Kit (R&D Systems). Cells were maintained with 5% CO2 in a 
water-jacketed incubator at 37 °C for 2–5 weeks. Mineralized osteogenic cells were identified by Alizarin Red S 
(Sigma-Aldrich) staining. Adipocytes were identified by characteristic production of lipid droplets and staining 
with an anti-FABP antibody (R&D Systems). Chondrocytic cells were identified using an Alcian Blue 8GX solu-
tion (Sigma-Aldrich).
RNA isolation and quantitative real-time PCR. Sorted cells were collected in TRIzol reagent (Ambion) 
and mRNA was purified using a PureLink RNA Micro kit (Invitrogen). Reverse transcription and quantita-
tive real-time PCR were performed using a One Step SYBR Prime Script PLUS RT-PCR kit (TAKARA) and an 
Applied Biosystems StepOnePlusTM (Applied Biosystems). Gene expression data was normalized to Gapdh. The 
sequences of primers for each gene were as follows: Gapdh, 5′-TGTGTCCGTCGTGGATCTGA-3′ (forward) and 
5′-TTGCTGTTGAAGTCGCAGGAG-3′ (reverse); Runx2 (Type II isoform), 5′-CCAGCCACCGAGACCAACC-3′ 
(forward) and 5′-GTTTGACGCCATAGTCCCTCC-3′ (reverse); LepR, 5′-TCAGAATTTTGGGTGGAAAA-3′ 
(forward) and 5′-GTCCAGGTGAGGAGCAAGAG-3′ (reverse); PDGFRa, 5′-AGCAAACATCTTGACTTGGG 
AACA-3′ (forward) and 5′-ACTTGCATCATTCCCGGACAC-3′ (reverse); CXCL12, 5′-CCAGAGCCAACGTC 
AAGCAT-3′ (forward) 5′-CAGCCGTGCAACAATCTGAA-3′ (reverse).
Microcomputed tomography analysis. Femora were fixed in 70% ethanol. Three-dimensional (3D) 
reconstructions of distal femora were obtained by micro-computed tomography (μCT) (ScanXmate-A080, 
Comscan Tecno). Morphological indices were calculated in trabecular bones located from 0.5 to 1.5 mm from the 
growth plates using image analysis software (TRI/3D-BON, Ratoc Syatem Engineering).
Statistics. The results were expressed as mean ± SD. Data were evaluated by unpaired Student′s t-tests. 
Experiments were performed three times and similar results were obtained. Statistical analyses were performed 
with Graph Pad Prism 6. P < 0.05 was considered significant.
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